Longevity-focussed healthtech startup Biopeak has bagged $2.7 Mn (INR 24.8 Cr) in a fresh funding round led by Nikhil Kamath’s venture capital firm NKSquared, which is an existing investor in the startup. The fresh capital will be channelled towards scaling operations, including the launch of a new flagship centre in Bengaluru as well as expand its team. Besides, Biopeak also intends to expand its specialist clinics and diagnostics footprint, advance proprietary AI and research infrastructure and deepen its clinical governance and advisor network. Founded in 2024 by Rishi Pardal and Shiva Subramanian, Biopeak offers comprehensive healthcare with cellular insights, imaging, and AI for personalised health and long-term vitality, its website says. The startup is working on a tech that detects risks early, maps the body’s internal state and generates personalised insights based on an individual’s biology and lifestyle. Its tech sees it profile 130+ biomarker blood panels, genetic and epigenetic profiling, gut and oral microbiome mapping, hormonal analysis, salivary cortisol rhythms, and whole-exome functional genomics, paired with high-resolution imaging such as MRI, CT, DXA, ECHO, and Carotid IMT. Moreover, Biopeak collaborates with institutions like IISc and Longevity India to better contextualise healthspan data for South Asian genetics, environment, and lifestyle.… Read MoreInc42 Media
